An investigation on behalf of investors in Neos Therapeutics Inc (NASDAQ:NEOS) shares over potential wrongdoing at Neos Therapeutics was announced and NASDAQ:NEOS stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/12/2016 -- An investigation on behalf of investors in shares of Neos Therapeutics Inc (NASDAQ:NEOS) was announced over potential breaches of fiduciary duties by certain directors at Neos Therapeutics.
Investors who purchased shares of Neos Therapeutics Inc (NASDAQ:NEOS) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.
The investigation by a law firm concerns whether certain Neos Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
On October 19, 2015 Neos Therapeutics Inc announced that, on October 16, 2015, the Company received a notification from the U.S. Food and Drug Administration ('FDA') stating that, as part of its ongoing review of the Company's New Drug Application ('NDA') for Cotempla XR-ODT (Methylphenidate Extended Release Orally Disintegrating) 10 mg, 20mg, and 30 mg tablets, it has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.
Shares of Neos Therapeutics Inc (NASDAQ:NEOS) declined to as low as $11.53 per share on October 22, 2015.
On August 11, 2016, Neos Therapeutics Inc reported its second quarter 2016 financial results.
Shares of Neos Therapeutics Inc (NASDAQ:NEOS) declined to as low as $6.81 per share on August 11, 2016.
On September 9, 2016, NASDAQ:NEOS shares closed at $7.60 per share.
Those who purchased shares of Neos Therapeutics Inc have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com